Healthcare Industry News: Pulse Oximeter
News Release - September 10, 2008
Masimo Announces Desaturation Index 3D Alarm as Standard Feature in All Radical-7 Pulse CO-Oximetry DevicesIRVINE, Calif., Sept. 10 (HSMN NewsFeed) -- Masimo (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry and Measure-Through-Motion-and-Low-Perfusion pulse oximetry, today announced that all customers purchasing the Masimo Radical-7, the company's flagship product, will now receive Desat Index 3D Alarm as a standard feature.
Conventional Pulse Oximeters typically alarm based on large and isolated drops in oxygen saturation values, known as a "desaturation". However, published research has shown that a cycle of moderate desaturations has been shown to precede respiratory failure in hospitalized patients(1,2). Masimo Desat Index 3D Alarm enables advanced notification of these conditions, based on clinician-specified severity and number of desaturations occurring in a specified period of time.
Michael O'Reilly, MD, Masimo Executive Vice President of Medical Affairs, stated; "When combined with the proven ability of Masimo Signal Extraction Technology (SET) to dramatically reduce false desaturation alarms and improve the detection of true desaturations, Masimo Desat Index 3D Alarm advances patient care by allowing earlier intervention to prevent adverse respiratory events."
Joe Kiani, Chairman and CEO of Masimo, stated; "Masimo has been selling Desat Index 3D Alarm as an option for almost three years. In light of our soon-to-be released breakthrough innovation, noninvasive and continuous hemoglobin monitoring technology, we are pleased to now offer Desat Index 3D Alarm as a standard feature."
(1) Continuous Pulse Oximeter Monitoring for Inapparent Hypoxemia after Long Bone Fractures. Wong MW, Tsui HF, Yung SH, Chan KM, Cheng JC. Journal of Trauma-Injury Infection & Critical Care. 56(2):356-362, February 2004.
(2) Occurance and Mechanisms of Sudden Oxygen Desaturation in Infants Who Sleep Face Down. Patel AL, Paluszynska D, Harris KA, Thach BT.Pediatrics. 2003 Apr;111(4 Pt 1):e328-32.
Masimo (NASDAQ: MASI ) develops innovative monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through-Motion-and-Low-Perfusion pulse oximetry, known as Masimo SET, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at http://www.masimo.com.
Forward Looking Statements
This press release may include forward-looking statements. These forward- looking statements are based on current expectations about future events affecting us and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control, including: risks related to our assumption that the addition of Desat Index 3D Alarms as a standard feature on the Masimo Radical-7 will lead to additional device sales, as well as other factors discussed in the "Risk Factors" section of our quarterly report on Form 10-Q for the quarter ended June 28, 2008, filed with the Securities and Exchange Commission on August 5, 2008. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the risk factors contained in our quarterly report on Form 10-Q for the quarter ended June 28, 2008, whether as a result of new information, future events or otherwise, except as may be required under the federal securities laws.
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57, Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.